Objective  To investigate the efficacy of Tongxie Yaofang (TXYF) combined with turtle-shell-partitioned moxibustion (TSPM) and meridian massage (MM) in Diarrhea-predominant irritable bowel syndrome with diarrhea (IBS-D) patients with liver depression and spleen deficiency.

Methods  Patients with IBS-D characterized by liver stagnation and spleen deficiency from June 2022 to June 2024 at the Department of Gastroenterology, Nantong Hospital of Traditional Chinese Medicine were recruited, and randomly equally divided into the TXYF group and the combined therapy group. The primary outcome indicator was the overall effectiveness rate. Secondary outcome indicators included the traditional Chinese medicine syndrome score (TCM- SS), scores of the irritable bowel syndrome quality of life scale (IBS-QOL), the irritable bowel syndrome symptom severity scale (IBS-SSS), the Hamilton anxiety scale (HAMA), the Hamilton depression scale (HAMD), and serum levels of interleukin-10 (IL-10) and interleukin-12 (IL-12).

Results  A total of ninety-six patients were included, with 48 patients in both the TXYF group and the combined therapy group. After two weeks of treatment, the overall effectiveness rate in the combined therapy group was significantly higher than that in the TXYF group (P<0.05). Furthermore, the TCM-SS total score, IBS-SSS score, HAMA score, HAMD score, and serum IL-12 levels of the combined therapy group were significantly lower than those of the TXYF group, while the IBS-QOL score and serum IL^-10 levels were significantly higher than those of the TXYF group (P<0.05).

Conclusion  TXYF combined with TSPM and MM can improve the clinical treatment effects of IBS-D by regulating the levels of inflammation.

1.李艳波. 舒肝解郁胶囊联合马来酸曲美布汀片治疗腹泻型肠易激综合征合并抑郁状态的研究[J]. 数理医药学杂志, 2022, 35(3): 382-384. [Li YB. Study on Shugan JieYu capsules combined with trimethoprim maleate tablets in the treatment of diarrhea-type irritable bowel syndrome complicated with depression[J]. Journal of Mathematical Medicine, 2022, 35(3): 382-384.] DOI: 10.3969/j.issn.1004-4337.2022.03.022.

2.Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5(10): 908-917. DOI: 10.1016/S2468-1253(20)30217-X.

3.胡燕芳, 安明伟, 唐勇, 等. 基于网络药理学及分子对接探讨乌梅丸治疗腹泻型肠易激综合征的作用机制[J]. 西部医学, 2023, 35(4): 506-511. [Hu YF, An  MW, Tang Y, et al. The mechanism of action of Wumei pill in the treatment of diarrhea-predominant irritable bowel syndrome based on network pharmacology and molecular docking[J]. Medical Journal of West China, 2023, 35(4): 506-511.] DOI: 10.3969/j.issn.1672-3511.2023.04.008.

4.管洁, 邓娜, 蔺晓源, 等. 腹泻型肠易激综合征及其中医病证结合动物模型的研究进展[J]. 中医药信息, 2023, 40(5): 73-78. [Guan J, Deng N, Lin XY, et al. Study advances in animal models of IBS-D and TCM combination of disease and syndrome[J]. Information on Traditional Chinese Medicine, 2023, 40(5): 73-78.] DOI: 10.19656/j.cnki.1002-2406.20230512.

5.Paine P. Review article: current and future treatment approaches for pain in IBS[J]. Aliment Pharmacol Ther, 2021, 54 Suppl 1: S75-S88. DOI: 10.1111/apt.16550.

6.Black CJ, Ford AC. Best management of irritable bowel syndrome[J]. Frontline Gastroenterol, 2020, 12(4): 303-315. DOI: 10.1136/flgastro-2019-101298.

7.余良, 谢洁如, 李建峰, 等. 腹泻型肠易激综合征肝郁脾虚证中药内服法研究进展[J]. 中国医药科学, 2021, 11(11): 36-41. [Yu L, Xie JR, Li JF, et al. The progress of the research on oral administration of Chinese materia medica for diarrhea-predominant irritable bowel syndrome with liver depression and spleen deficiency syndrome[J]. China Medicine and Pharmacy, 2021, 11(11): 36-41.] DOI: 10.3969/j.issn.2095-0616.2021.11.011.

8.卢瑶瑶, 柴玉娜, 秦崇臻, 等. 痛泻要方治疗腹泻型肠易激综合征的作用机制研究进展[J]. 辽宁中医杂志, 2024, 51(2): 202-206. [Lu YY, Chai YN, Qin  CZ, et al. Research progress on mechanism of Tongxie Yaofang in clinical treatment of irritable bowel syndrome with diarrhea[J]. Liaoning Journal of Traditional Chinese Medicine, 2024, 51(2): 202-206.] DOI: 10.13192/j.issn.1000-1719.2024.02.049.

9.庄威, 肖京, 曹昺焱, 等. 隔物灸治疗肠易激综合征的临床研究进展[J]. 中国中医药现代远程教育, 2021, 19(11): 200-203. [Zhuang W, Xiao J, Cao BY, et al. Clinical Research progress on indirect moxibustion in the treatment of irritable bowel syndrome[J]. Chinese Medicine Modern Distance Education of China, 2021, 19(11): 200-203.] DOI: 10.3969/j.issn.1672-2779.2021.11.074.

10.庞根生, 陈璋莲, 洪珏. 针刺加隔鳖甲灸治疗腹泻型肠易激综合征疗效观察[J]. 针灸推拿医学(英文版), 2016, 14(1): 22-25. [Pang Gs, Chen Zl, Hong J. Therapeutic observation of acupuncture plus turtle-shell-partitioned moxibustion for diarrhea-predominant irritable bowel syndrome[J]. Journal of Acupuncture and Tuina Science, 2016, 14(1): 22-25.] DOI: 10.1007/s11726-016-0895-5.

11.张冠中. 针刺配合摩腹法治疗腹泻型肠易激综合征的临床研究[D]. 广州: 广州中医药大学, 2016. https://cdmd.cnki.com.cn/Article/CDMD-10572-1016208113.htm.

12.中华医学会消化病学分会胃肠功能性疾病协作组, 中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见[J]. 中华消化杂志, 2020, 40(12): 803-818. DOI: 10.3760/cma.j.cn311367-20201116-00660.

13.中华中医药学会脾胃病分会. 肠易激综合征中医诊疗专家共识意见(2017)[J]. 中医杂志, 2017, 58(18): 1614-1620. DOI: 10.13288/j.11-2166/r.2017.18.024.

14.史先芳, 刘铁梅, 何桂钧. 痛泻要方对腹泻型肠易激综合征患者炎症因子表达的影响[J]. 哈尔滨医科大学学报, 2024, 58(1): 15-19. [Shi XF, Liu TM, He GJ. Effect of Tongxie decoction on expression of inflammatory factors in patients with diarrheal irritable bowel syndrome[J]. Journal of Harbin Medical University, 2024, 58(1): 15-19.] DOI: 10.20010/j.issn.1000-1905.2024.01.0015.

15.黄丽清. 匹维溴铵联合益生菌对腹泻型肠易激综合征患者肠道菌群及生活质量的影响[J]. 黑龙江医药科学, 2023, 46(1): 188-189, 191. [Huang LQ. Effect of pivinonium combined with probiotics on gut microbiota and quality of life in patients with diarrheal irritable bowel syndrome[J]. Heilongjiang Medicine and Pharmacy, 2023, 46(1): 188-189, 191.] DOI: 10.3969/j.issn.1008-0104.2023.01.075.

16.王栩芮, 傅文斌, 孙弋淇, 等. 痛泄要方缓解肝郁脾虚证腹泻型肠易激综合征患者内脏高敏的临床疗效 [J]. 中国实验方剂学杂志, 2022, 28(9): 97-102. [Wang  XR, Fu WB, Sun YQ, et al. The clinical effect of relieving liver depression and spleen deficiency in irritable bowel syndrome[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2022, 28(9): 97-102.] DOI: 10.13422/j.cnki.syfjx.20220992.

17.张娇, 陈婷, 刘靖, 等. 痛泻要方联合艾条灸治疗腹泻型肠易激综合征效果及对免疫球蛋白、血清炎症因子水平的影响[J]. 中国医药导报, 2023, 20(35): 141-145. [Zhang J, Chen T, Liu J, et al. The effect of diarrhea and its effect on immunoglobulin and serum inflammatory factor levels[J]. China Medical Herald, 2023, 20(35): 141-145.] DOI: 10.20047/j.issn1673-7210.2023.35.31.

18.霍永利, 毛竞宇, 侯姿蕾, 等. 温经通络中药热膏摩联合痛泻药方治疗肝郁脾虚证腹泻型肠易激综合征疗效观察[J]. 中华中医药杂志, 2021, 36(9): 5689-5692. [Huo YL, Mao JY, Hou ZL, et al. Curative effect observation of Wenjing Tongluo Hot Ointment combined with Tongxie Yaofang on diarrhea-type irritable bowel syndrome of liver depression and spleen deficiency[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2021, 36(9): 5689-5692.] https://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_zgyyxb202109137&dbid=WF_QK.

19.王瑶嘉, 任媛媛, 赵卫锋. 基于“五脏一体观”理论探讨针灸治疗腹泻型肠易激综合征的辨治思路[J]. 辽宁中医药大学学报, 2024-08-19. [Wang YJ, Ren YY, Zhao WF. Discussion on differentiation and treatment of diarrhea-predominant irritable bowel syndrome with acupuncture and moxibustion based on the theory of 'Five Viscera Integrated View[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2024-08-19.] http://kns.cnki.net/kcms/detail/21.1543.r.20240816.1532.020.html.

20.王桂群, 许二平, 刘雅琳, 等. 四神丸对肠易激合并抑郁模型大鼠的作用与机制研究[J]. 中国中医基础医学杂志, 2024, 30(5): 807-813. [Wang GQ, Xu EP, Liu YL, et al. Study on the effect and mechanism of Sishen pill on irritable bowel syndrome combined with depression model rats[J]. Journal of Basic Chinese Medicine, 2024, 30(5): 807-813.] DOI: 10.19945/j.cnki.issn.1006-3250.2024.05.020.

21.占道伟, 刘军, 徐颖梅, 等. 调神健脾针刺法联合电针治疗腹泻型肠易激综合征的疗效观察及对肥大细胞活化的影响[J]. 上海针灸杂志, 2024, 43(6): 594-598. [Zhan  DW, Liu J, Xu YM, et al. Observation on the efficacy of Tiao Shen Jian Pi acupuncture combined with electroacupuncture in the treatment of irritable bowel syndrome-diarrheal and its effect on mast cell activation[J]. Shanghai Journal of Acupuncture and Moxibustion, 2024, 43(6): 594-598.] DOI: 10.13460/j.issn.1005-0957.2024.06.0594.

22.Zheng H, Zhang C, Zhang J, et al. "Sentinel or accomplice": gut microbiota and microglia crosstalk in disorders of gut-brain interaction[J]. Protein Cell, 2023, 14(10): 726-742. DOI: 10.1093/procel/pwad020.